Study guide

1.17 Inborn Errors of Metabolism & Storage Disorders

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.17 Inborn Errors of Metabolism & Storage Disorders

Key Takeaways Explain This Topic AI

Most classic IEMs are autosomal recessive; OTC deficiency is the major X-linked urea-cycle exception genetic counselors must recognize on pedigree and newborn presentation

Phenylketonuria (PAH) requires lifelong Phe control; maternal PKU teratogenicity makes preconception diet optimization a core counseling goal

Classic galactosemia (GALT) presents with feeding intolerance, E. coli sepsis risk, cataracts, and later ovarian failure—immediate lactose/galactose restriction is lifesaving

Lysosomal storage disorders (Gaucher, Tay-Sachs, Pompe) differ by enzyme, substrate, ethnicity carrier rates, and whether enzyme replacement or supportive care is available

Fatty-acid oxidation defects such as MCADD cause hypoketotic hypoglycemia with fasting stress and are major newborn-screening targets with avoidance-of-fasting counseling

Last updated: August 2026

1.17 Inborn Errors of Metabolism & Storage Disorders

Quick Answer: Treat IEMs as pathway failures: substrate buildup ± product deficiency. Most are AR; flag OTC as X-linked. PKU = Phe diet + maternal PKU counseling; galactosemia = stop lactose immediately; urea-cycle = hyperammonemia emergency; LSDs = enzyme/substrate logic (Gaucher/Pompe often ERT-eligible; Tay-Sachs not); MCADD = no prolonged fasting.

Domain 1C metabolic items rarely ask you to recite every enzyme Km. They ask whether the presentation , inheritance , NBS status , and management lever fit. Genetic counselors translate biochemical disease into family risk, reproductive options, and coordinated care with metabolic genetics.

How to Organize Any IEM on the Exam

  • Axis What to extract from a vignette
  • Pathway class AA (e.g., PKU), CHO (galactosemia), urea cycle, FA oxidation, lysosomal storage
  • Inheritance Usually AR ; OTC is the high-yield X-linked urea-cycle disorder
  • Tempo Neonatal crisis vs infantile neurodegeneration vs adult visceral disease
  • Lab signature Hyperammonemia, hypoketotic hypoglycemia, elevated Phe, enzyme assay, gene panel
  • Lever Diet, dialysis/scavengers, ERT/SRT, gene therapy (disease-specific), supportive care

Exam trap: “Metabolic = always AR” fails when the stem is a boy with hyperammonemia and a mildly symptomatic mother—think OTC .

Phenylketonuria (PKU)

PKU is caused by biallelic pathogenic variants in PAH (phenylalanine hydroxylase), blocking conversion of Phe → tyrosine. Untreated classic PKU produces irreversible intellectual disability, seizures, microcephaly, and eczema/musty odor phenotypes historically described before NBS. In screened populations, the counseling focus shifts to diet adherence , tyrosine sufficiency , and maternal PKU .

  • Feature Counseling anchor
  • Gene / inheritance PAH · autosomal recessive
  • Core biochemistry Elevated phenylalanine; BH4-responsive subset exists (cofactor pathway)

Treatment Phe-restricted diet ± medical foods; sapropterin in responsive patients; pegvaliase in selected adults

Maternal PKU High maternal Phe is teratogenic → cardiac defects, microcephaly, growth restriction, ID in offspring— optimize diet before conception

Recurrence 25% for each pregnancy of carrier couple; offer carrier testing to partner of affected/known carrier

Maternal PKU is a classic cross-domain item: it is not “the fetus has PKU”—it is teratogenicity from maternal hyperphenylalaninemia , so even a fetus without biallelic PAH disease alleles is at risk if mother is poorly controlled.

Galactosemia

Classic galactosemia is usually GALT deficiency (galactose-1-phosphate uridylyltransferase), AR. After milk feeds begin, infants may show vomiting, failure to thrive, hepatotoxicity, coagulopathy, cataracts, and life-threatening E. coli sepsis . Immediate elimination of lactose/galactose (soy or elemental formulas as directed by metabolic team) is the acute intervention.

  • Feature Counseling anchor
  • Gene GALT (classic); also consider GALK1 , GALE for related disorders

NBS Often detected by enzyme/metabolite screens—confirm with definitive testing; Duarte variant counseling differs from classic

Long-term Even with diet, speech/language issues, tremor, and premature ovarian insufficiency in females are important anticipatory guidance topics

Inheritance counseling AR; cascade carrier testing; dietary education for infant feeding

Do not confuse Duarte galactosemia (partial activity, often milder management) with classic disease when the stem specifies life-threatening neonatal sepsis and cataracts.

Urea-Cycle Disorders

Urea-cycle defects impair ammonia detoxification → hyperammonemia , often with respiratory alkalosis early, encephalopathy, and risk of death or neurologic injury. Most enzyme defects are AR ( CPS1, ASS1, ASL, ARG1 ), but ornithine transcarbamylase (OTC) deficiency is X-linked and the most common urea-cycle disorder.

Disorder Inheritance High-yield clinical note

OTC deficiency X-linked Males often severe neonatal; heterozygous females variable (skewed X-inactivation); postpartum and catabolic triggers

CPS1, citrullinemia (ASS1), ASL, arginase AR Hyperammonemia ± citrulline/argininosuccinate signatures guiding biochemical differential

Acute management theme — Stop protein, give calories, ammonia scavengers, dialysis if needed—then definitive enzymatic/molecular diagnosis

Counseling pearl: a pedigree with affected males, mild or episodic symptoms in females, and maternal-line transmission supports OTC until proven otherwise—and carrier females need crisis-prevention education (illness, surgery, postpartum).

Lysosomal Storage Disorders: Gaucher, Tay-Sachs, Pompe

Lysosomal storage disorders (LSDs) share impaired degradation of macromolecules inside lysosomes. For CGC purposes, master enzyme, substrate logic, ethnicity carrier enrichment when relevant, CNS involvement, and whether enzyme replacement therapy (ERT) exists.

Disorder Gene / enzyme Inheritance Hallmarks Therapy theme

Gaucher disease GBA / glucocerebrosidase AR Hepatosplenomegaly, cytopenias, bone crises; type 1 non-neuronopathic vs neuronopathic types 2/3; ↑ Ashkenazi carrier frequency ERT / substrate reduction for visceral disease; neuronopathic forms limited CNS benefit

Tay-Sachs HEXA / hexosaminidase A AR Infantile: regression, cherry-red macula, hyperacusis, macrocephaly; Ashkenazi & other founder populations historically high carrier rates Supportive; no standard ERT for CNS disease—carrier screening historically paradigm-shifting

Pompe disease GAA / acid α-glucosidase (acid maltase) AR Infantile: hypotonia, hypertrophic cardiomyopathy, respiratory failure; late-onset: progressive myopathy ± respiratory involvement ERT available; early diagnosis changes survival in infantile form

Ashkenazi Jewish carrier screening historically prioritized Tay-Sachs (and later expanded panels including Gaucher and others). Exam items may still use ethnicity as a pretest-probability hint, but modern practice emphasizes offering appropriate carrier screening based on guidelines and patient ancestry without assuming a single ethnicity box .

Gaucher counseling traps: heterozygous GBA variants also confer increased Parkinson disease risk—mention when relevant without equating carrier status to Gaucher disease. Distinguish type 1 (visceral, ERT-responsive theme) from neuronopathic types when the stem includes horizontal gaze palsy or rapid neurodegeneration.

Pompe counseling traps: infantile Pompe looks like a floppy infant with cardiomegaly—pair muscle + heart. Late-onset Pompe can mimic limb-girdle dystrophy; CK may be elevated; dried-blood-spot enzyme assay and GAA sequencing enter the diagnostic path.

Fatty-Acid Oxidation Defects (Focus: MCADD)

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) ( ACADM , AR) is the highest-yield FAO disorder. Impaired β-oxidation → hypoketotic hypoglycemia during fasting or intercurrent illness, with risk of sudden death if unrecognized. Newborn screening has dramatically reduced mortality when paired with avoidance of prolonged fasting , prompt glucose support during illness, and emergency letters.

  • Feature Counseling anchor
  • Trigger Prolonged fasting, vomiting illness, perioperative NPO without IV glucose
  • Labs Hypoketotic hypoglycemia; characteristic acylcarnitine profile (e.g., elevated C8)
  • Management message “Never long fasts”; sick-day plan; medic alert / emergency protocol
  • Family AR recurrence 25%; siblings may need urgent evaluation even if well-appearing if NBS pending/missed

Other FAO defects (VLCAD, LCHAD, carnitine cycle) share the fasting-intolerance theme; LCHAD additionally links to maternal HELLP/AFLP risk in heterozygous mothers carrying an affected fetus—a reproductive counseling cross-link.

Diagnostic Strategy Snapshot for Metabolic Stems

Stabilize (glucose, ammonia, diet stop/start) before exhaustive testing when the child is crashing.

Draw critical samples (ammonia, blood gas, glucose, lactate, acylcarnitines, plasma AAs, urine organic acids) as directed by metabolic team.

Pair biochemistry with gene panel / exome when the pathway is broad.

Offer cascade testing and reproductive counseling once the familial variant is known.

Tie NBS positive results to confirmatory testing—do not counsel a definitive diagnosis from an unconfirmed screen alone.

This metabolic toolkit returns in Domain 3 (NBS vs diagnostic testing) and Domain 4 (delivering life-limiting neurodegenerative diagnoses such as infantile Tay-Sachs).